Drug delivery system based on cationic siloxanyl macromonomers

1. A matrix controlled diffusion drug delivery system comprising a therapeutically effective amount of one or more pharmaceutically active agents covalently bound to a polymerization product of a monomeric mixture comprising one or more silicon-containing monomers of Formula I:

wherein L can be the same or different and is selected from the group consisting of urethanes, carbonates, carbamates, carboxyl ureidos, sulfonyls, a straight or branched, substituted or unsubstituted C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, a substituted or unsubstituted C 1 -C 20 ester group, an alkyl ether, cycloalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether, a polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocyclolalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, a C 5 -C 30 fluoroaryl group, or a hydroxyl substituted alkyl ether and combinations thereof; X − is at least a single charged counter ion; n is an integer from 1 to about 300; R1, R2, R3, R4, R5, R6, R7 and R8 are independently hydrogen, a straight or branched, substituted or unsubstituted C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, a C 1 -C 20 ester group, an alkyl ether, cycloalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether, a polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocyclolalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, fluorine, a C 5 -C 30 fluoroaryl group, or a hydroxyl group, and V is independently a polymerizable ethylenically unsaturated organic radical; wherein the matrix controlled diffusion drug delivery system is sized and configured for back of the eye delivery.

2. The matrix controlled diffusion drug delivery system of claim 1 , wherein X − is selected from the group consisting of Cl − , Br − , I − , CF 3 CO 2 − , CH 3 CO 2 − , HCO 3 − , CH 3 SO 4 − , p-toluenesulfonate, HSO 4 − , H 2 PO 4 − , NO 3 − , CH 3 CH(OH)CO 2 − , SO 4 2− , CO 3 2− , HPO 4 2− and mixtures thereof.

3. The matrix controlled diffusion drug delivery system of claim 1 , wherein X − is at least a single charged counter ion and is selected from the group consisting of Cl − , Br − , I − , CF 3 CO 2 − , CH 3 CO 2 − , HCO 3 − , CH 3 SO 4 − , p-toluenesulfonate, HSO 4 − , H 2 PO 4 − , NO 3 − , and CH 3 CH(OH)CO 2 − and mixtures thereof.

4. The matrix controlled diffusion drug delivery system of claim 1 , wherein the monomer is selected from the group consisting of monomers having the following formulae:

5. The matrix controlled diffusion drug delivery system of claim 1 , wherein the one or more pharmaceutically active agents is selected from the group consisting of an anti-glaucoma agent, anti-cataract agent, anti-diabetic retinopathy agent, anti-cancer agent, immune modulator agent, anti-clotting agent, anti-tissue damage agent, anti-inflammatory agent, anti-fibrous agent, non-steroidal anti-inflammatory agent, antibiotic, anti-pathogen agent, cycloplegic agent, miotic agent, mydriatic agent and mixtures thereof.

6. The matrix controlled diffusion drug delivery system of claim 1 , wherein the one or more pharmaceutically active agents is selected from the group consisting of an anticholinergic, anticoagulant, antifibrinolytic, antihistamine, antimalarial, antitoxin, hormone, immunosuppressive, thrombolytic, vitamin, protein, desensitizer, prostaglandin, amino acid, antiallergenic and mixtures thereof.

7. The matrix controlled diffusion drug delivery system of claim 1 , wherein the monomeric mixture comprises one or more other monomers or prepolymers.

8. The matrix controlled diffusion drug delivery system of claim 7 , wherein the one or more monomers are selected from the group consisting of methyl methacrylate, 2-ethylhexyl methacrylate, benzyl methacrylate, 2-phenylethyl methacrylate, dimethyl itaconate, trifluoromethyl methacrylate, hexafluoroisopropyl methacrylate, bis(hexafluoroisopropyl)methacrylate, 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, acrylic acid, itaconic acid, acrylic anhydride, methacrylic anhydride, maleic anhydride, itaconic anhydride, glycerol methacrylate, hydroxypropyl methacrylate, N,N-dimethylacrylamide, acrylamide, N-methylacrylamide, N-vinylpyrrolidione, N-isopropylacrylamide, hydroxybutyl methacrylate and mixtures thereof.

9. The matrix controlled diffusion drug delivery system of claim 1 , in a form of a solution, suspension, solution/suspension, microsphere or nanosphere.

10. The matrix controlled diffusion drug delivery system of claim 1 , in a form of a semi-solid or solid article suitable for ocular implant.

11. A process for preparing a matrix controlled diffusion drug delivery system sized and configured for back of the eye delivery, the process comprising polymerizing a therapeutically effective amount of one or more pharmaceutically active agents with a monomeric mixture comprising one or more silicon-containing monomers of Formula I:

wherein L can be the same or different and is selected from the group consisting of urethanes, carbonates, carbamates, carboxyl ureidos, sulfonyls, a straight or branched, substituted or unsubstituted C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, a substituted or unsubstituted C 1 -C 20 ester group, an alkyl ether, cycloalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether, a polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocyclolalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, a C 5 -C 30 fluoroaryl group, or a hydroxyl substituted alkyl ether and combinations thereof; X − is at least a single charged counter ion; n is an integer from 1 to about 300; R1, R2, R3, R4, R5, R6, R7 and R8 are independently hydrogen, a straight or branched C 1 -C 30 alkyl group, a C 1 -C 30 fluoroalkyl group, a C 1 -C 20 ester group, an alkyl ether, cycloalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether, a polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocyclolalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, fluorine, a C 5 -C 30 fluoroaryl group, or a hydroxyl group; and V is independently a polymerizable ethylenically unsaturated organic radical, to provide a matrix controlled diffusion drug delivery system wherein the therapeutically effective amount of one or more pharmaceutically active agents is covalently bound to the polymerization product.

12. The process of claim 11 , wherein n is 2 to about 100, R1, R2, R3, R4, R5, R6, R7 and R8 are independently a straight or branched C 1 -C 30 alkyl group, and V is independently an ester or amide of acrylic or methacrylic acid.

13. The process of claim 11 , wherein x is 2 to about 100, R1, R2, R3, R4, R5, R6, R7 and R8 are independently a straight or branched C 1 -C 6 alkyl group, and V is independently an ester or amide of acrylic or methacrylic acid.

14. The process of claim 11 , wherein n is 2 to about 100, R1, R2, R3, R4, R5, R6, R7 and R8 are independently a straight or branched C 1 -C 6 alkyl group, X— is Br— and V is independently an ester or amide of acrylic or methacrylic acid.

15. The process of claim 11 , wherein the one or more pharmaceutically active agents is selected from the group consisting of an anti-glaucoma agent, anti-cataract agent, anti-diabetic retinopathy agent, anti-cancer agent, immune modulator agent, anti-clotting agent, anti-tissue damage agent, anti-inflammatory agent, anti-fibrous agent, non-steroidal anti-inflammatory agent, antibiotic, anti-pathogen agent, cycloplegic agent, miotic agent, mydriatic agent and mixtures thereof.

16. The process of claim 11 , wherein the one or more pharmaceutically active agents is selected from the group consisting of an anticholinergic, anticoagulant, antifibrinolytic, antihistamine, antimalarial, antitoxin, hormone, immunosuppressive, thrombolytic, vitamin, protein, desensitizer, prostaglandin, amino acid, antiallergenic and mixtures thereof.

17. The process of claim 11 , wherein the monomeric mixture comprises one or more other monomers or prepolymers.

18. The process of claim 17 , wherein the one or more monomers are selected from the group consisting of methyl methacrylate, 2-ethylhexyl methacrylate, benzyl methacrylate, 2-phenylethyl methacrylate, dimethyl itaconate, trifluoromethyl methacrylate, hexafluoroisopropyl methacrylate, bis(hexafluoroisopropyl)methacrylate, 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, acrylic acid, itaconic acid, acrylic anhydride, methacrylic anhydride, maleic anhydride, itaconic anhydride, glycerol methacrylate, hydroxypropyl methacrylate, N,N-dimethylacrylamide, acrylamide, N-methylacrylamide, N-vinylpyrrolidione, N-isopropylacrylamide, hydroxybutyl methacrylate and mixtures thereof.

19. The process of claim 11 , wherein the matrix controlled diffusion drug delivery system is in a form of a solution, suspension, solution/suspension, microsphere or nanosphere.

20. The process of claim 11 , wherein the matrix controlled diffusion drug delivery system is in a form of a semi-solid or solid article suitable for ocular implant.